Literature DB >> 16707530

Efficacy of nitroglycerin inhalation in reducing pulmonary arterial hypertension in children with congenital heart disease.

P Goyal1, U Kiran, S Chauhan, R Juneja, M Choudhary.   

Abstract

BACKGROUND: There has been a renewed interest in nitric oxide donor drugs, such as nitroglycerin, delivered by the inhalational route for treatment of pulmonary arterial hypertension (PAH). We investigated the acute effects of inhaled nitroglycerin on pulmonary and systemic haemodynamics in children with PAH associated with congenital heart disease.
METHODS: Nineteen children with acyanotic congenital heart disease and a left to right shunt with severe PAH, undergoing routine diagnostic cardiac catheterization were included in this study. Systolic, diastolic and mean systemic as well as pulmonary artery pressures, right atrial pressure and pulmonary capillary wedge pressure (PCWP) were recorded and systemic vascular resistance index (SVRI) and pulmonary vascular resistance index (PVRI) were calculated at room air, following 100% oxygen as well as after nitroglycerin inhalation in all patients.
RESULTS: Systolic, diastolic and mean pulmonary artery pressure and PVRI decreased significantly, whereas heart rate, systolic, diastolic and mean systemic arterial pressure, PCWP and SVRI did not change significantly following 100% oxygen or inhalation of nitroglycerin.
CONCLUSION: Inhaled nitroglycerin significantly decreases systolic, diastolic and mean pulmonary artery pressure as well as PVRI without affecting systemic haemodynamics, and thus can be used as a therapeutic modality for acute reduction of PAH in children with congenital heart disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707530     DOI: 10.1093/bja/ael112

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  11 in total

1.  Is nitroglycerin effective in treatment of haemoptysis?

Authors:  Yi-pin Zhou; Qi Guo; Xiao-ke Chen; Guo Huang
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

Review 2.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

Review 3.  Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease.

Authors:  Monnipa Suesaowalak; John P Cleary; Anthony C Chang
Journal:  World J Pediatr       Date:  2010-02-09       Impact factor: 2.764

Review 4.  Pharmacologic management of perioperative pulmonary hypertension.

Authors:  Julie W Cheng; Adriano R Tonelli; Gosta Pettersson; Richard A Krasuski
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

Review 5.  Can nitric oxide-based therapy prevent bronchopulmonary dysplasia?

Authors:  Thomas M Raffay; Richard J Martin; James D Reynolds
Journal:  Clin Perinatol       Date:  2012-09       Impact factor: 3.430

Review 6.  New perspectives for the treatment of pulmonary hypertension.

Authors:  Reshma S Baliga; Raymond J MacAllister; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 7.  Inhaled therapy for the management of perioperative pulmonary hypertension.

Authors:  C A Thunberg; S T Morozowich; Harish Ramakrishna
Journal:  Ann Card Anaesth       Date:  2015 Jul-Sep

8.  Intravenous anesthesia with nitroglycerin inhalation for surgical abortion in a patient with severe congenital heart disease and low oxygen saturation: A case report.

Authors:  Zhengfeng Gu; Lian Xin; Zhiping Wang; Jun Wang
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

Review 9.  The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension.

Authors:  Charmaine C W Lo; Seyed M Moosavi; Kristen J Bubb
Journal:  Front Physiol       Date:  2018-08-23       Impact factor: 4.566

10.  Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Perioperative management in patients with pulmonary hypertension.

Authors:  Adriano R Tonelli; Omar A Minai
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.